Abstract
A conjugate of the antineoplastic drug daunomycin (DNM) with maleylated bovine serum albumin (MBSA-DNM) was taken up with high efficiency by a multidrug resistant variant, JD100, of the murine-macrophage tumour cell line, J774A.1, through the scavenger receptors resulting in cessation of DNA synthesis. In contrast, free DNM at similar concentrations did not affect the incorporation of [3H]thymidine by these cells. These results suggest that receptor-mediated intracellular delivery of antineoplastic drugs could be a viable and new approach for overcoming the problem of multidrug resistance in chemotherapy of neoplastic diseases.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibiotics, Antineoplastic / administration & dosage*
-
Antibiotics, Antineoplastic / metabolism
-
Antibiotics, Antineoplastic / pharmacology
-
Cell Survival / drug effects
-
Daunorubicin / administration & dosage*
-
Daunorubicin / metabolism
-
Daunorubicin / pharmacology
-
Drug Delivery Systems*
-
Drug Resistance, Multiple*
-
Endocytosis
-
Macrophages / metabolism
-
Maleates / pharmacology
-
Mice
-
Poly G / pharmacology
-
Receptors, Drug / metabolism*
-
Serum Albumin, Bovine / metabolism
-
Tumor Cells, Cultured
-
Verapamil / pharmacology
Substances
-
Antibiotics, Antineoplastic
-
Maleates
-
Receptors, Drug
-
Poly G
-
Serum Albumin, Bovine
-
Verapamil
-
Daunorubicin